Tag Archives: Hatch-Waxman

Trump Signs Economic and Trade Agreement with China

On January 15, 2020, President Trump signed a lengthy “Economic and Trade Agreement Between the Government of the [US] and the Government of [P. R. of China].” Chapter 1 is entitled “Intellectual Property”  that contains Sections on trade secrets, pharmaceuticals, … Continue reading

Posted in Trade Agreements | Tagged , , | Leave a comment

Cutting Through the Patent Thicket – The Little Bill that Couldn’t

A bill was recently proposed to “reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.” The bill would amend the patent statutes (s. 253 or title 35) for add … Continue reading

Posted in Drug Patent Term | Tagged , , , , , | Leave a comment

Senate Subcommittee on IP Feels our PAIN

In lengthy hearings conducted by the Senate Subcommittee on Intellectual Property (of the Committee on the Judiciary) on June 4th and 5th (Parts I and II; Part III will be held on June 11th), the Subcommittee, chaired by Senators Tillis … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Is the “Blocking Patent” Doctrine Part of the Obviousness Analysis?

Last year, in a lengthy split decision, a Fed. Cir. panel affirmed the district court’s ruling that four “add-on” patents that Acorda owned were invalid as obviousness in view of a number of prior art references (Acorda Ther., Inc. v. … Continue reading

Posted in Section 103 | Tagged , , , , , , , , | Leave a comment